11.2 Labeling & Packaging of Dispensed Drugs

11.2 Labeling & Packaging of Dispensed Drugs

Quick Answer: Under Rule 6800.3400, drugs dispensed to outpatients (other than hospital inpatients, and excluding radiopharmaceuticals under a separate part) must be labeled with pharmacy name/address/phone, patient name, prescription number, prescriber name, directions, manufacturer or distributor of the finished dosage form, drug name and strength, date of original issue or renewal, auxiliary labels as needed, and—after July 1, 2008—a physical description/ID code for legend drugs and non-original-container nonlegend drugs. Rule 6800.4150 and Minn. Stat. §151.212 add controlled-substance and opioid caution statements. Packaging must meet federal PPPA child-resistant requirements unless a lawful exemption applies.

Labeling is Area 3 competency 3.5; packaging is 3.6. Exam items often hide a missing element (manufacturer, physical description, opioid caution) inside an otherwise perfect vignette.

Outpatient Label Elements — Rule 6800.3400, Subp. 1

Except for radiopharmaceuticals, all drugs dispensed to or for a patient other than a hospital inpatient must include:

Small containers and med packs

• Subp. 2: If the immediate container is too small for full labeling, a partial label with at least patient name and Rx number may go on the container, with complete labeling on an appropriate outer container.
• Subp. 3: With consent of the patient, caregiver, or prescriber, a pharmacist may use a customized patient medication package meeting USP standards (rule cites USP chapter standards for med packs).
• Subp. 4–5: Veterinary labels add species, owner/facility identifiers, withdrawal times for food animals, and related items; radiopharmaceuticals follow 6800.8550.

Statutory Overlay — Minn. Stat. §151.212

Subdivision 1 requires a label permanently affixed to the immediate container received by the purchaser, bearing the manufacturer or distributor of the finished dosage form and all other information required by law and board rules.

Subdivision 2 (controlled substances / impairing drugs):

• Board rules must require notice when a CS (or other board-designated drug) alone or with alcohol may impair driving—implemented in practice by Rule 6800.4150.
• Whenever a prescription drug containing an opiate is dispensed for outpatient use, the label must prominently state: “Caution: Opioid. Risk of overdose and addiction.”

Subdivision 4 (accessible labels): Pharmacies must make reasonable efforts to inform the public (and known vision-impaired patients) that accessible container labels (large print, Braille, or other U.S. Access Board best-practice methods) are available at no additional cost on request, with capacity expectations phased so that by January 1, 2026 all pharmacies must be able to provide them timely (correctional-institution dispensing excluded).

Controlled-Substance Caution Labels — Rule 6800.4150

Drugs administered systemically as controlled substances under chapter 152 (and board CS parts), and other drugs the pharmacist judges appropriate, when dispensed to or for an adult outpatient (not hospital or nursing-home inpatient), must meet 6800.3400 and also bear:

“Caution: Taking this drug alone or with alcohol may impair your ability to drive.”

Controlled substances must also bear:

“Caution: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed.”

Stack this with the §151.212 opioid sentence when the product is an outpatient opiate. Missing any of these cautions is a classic labeling miss.

Packaging: Federal PPPA Child-Resistant Containers

The federal Poison Prevention Packaging Act (PPPA), enforced by the CPSC, requires special (child-resistant) packaging for most oral prescription drugs for household use. Minnesota practice must comply with that federal packaging floor:

• Default: dispense in child-resistant containers
• Patient may request non-child-resistant packaging (often a blanket or per-prescription request—document the request)
• Prescriber may request non-CRC for a particular prescription
• Manufacturer unit-of-use that is already CRC-compliant may be dispensed as packaged when appropriate

Do not invent Minnesota “CRC is optional for everyone over 65” shortcuts—age alone is not an automatic waiver. Institutional unit-dose systems and certain exempted products follow federal exemptions, not pharmacy convenience.

Beyond-Use Dating and Auxiliary Warnings (Practice Integration)

Rule 6800.3400 does not replace USP or Minnesota compounding BUD rules for compounded preparations (covered in the compounding chapter). For ordinary manufactured products, follow manufacturer dating, stability, and board expectations; use auxiliary labels for refrigeration, shake-well, take-with-food, photosensitivity, and similar high-risk use points. Physical description (tablet color/shape/imprint) is a patient-safety identification control, not decoration.

Common Exam Traps

Study Checklist

1. Recite the 6800.3400 outpatient checklist including manufacturer and physical description.
2. Add 6800.4150 dual CS cautions and the §151.212 opioid sentence.
3. Explain central-service labeling and small-container outer-label rules.
4. Apply PPPA CRC defaults and documented exceptions.
5. Know accessible label duties under §151.212, subd. 4.

If the label is incomplete, the dispense is incomplete—even when the clinical choice of drug was perfect.